1Y Close · As of Aug 26, 2026
Hugel operates in the Pharmaceuticals sector.
Legal name: Hugel, Inc.
In fiscal year 2025, Hugel (145020) reported revenue of 425.1 billion KRW, up 14.0% from 373.0 billion KRW a year earlier.
Operating profit was 200.9 billion KRW and net income was 147.0 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 3.14 trillion KRW, with a P/B of 3.20.
These figures can be verified in the DART filing (receipt no. 20260320000349).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 425.1B | 200.9B | 147.0B |
| 2024 | 373.0B | 166.2B | 143.1B |
| 2023 | 319.7B | 117.8B | 97.7B |
Recent Filings
Extraordinary Meeting Result
Officer/Major Shareholder Ownership Report
Independent Director Change Report
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: Treasury stock filings in the last 3 years: 1 disposal(s).
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-21 | Extraordinary Meeting Result |
| 2026-08-21 | Officer/Major Shareholder Ownership Report |
| 2026-08-21 | Independent Director Change Report |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-14 | Payment and Dispute Resolution |